Radiodermatitis Market Report by Product (Topical, Oral, Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2025-2033

Radiodermatitis Market Report by Product (Topical, Oral, Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A5638

Market Overview:

The global radiodermatitis market size reached USD 514.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 668.0 Million by 2033, exhibiting a growth rate (CAGR) of 2.94% during 2025-2033.

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 514.8 Million
Market Forecast in 2033
USD 668.0 Million
Market Growth Rate 2025-2033 2.94%


Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient’s life.

Radiodermatitis Market


Radiodermatitis Market Trends:

The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global radiodermatitis market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product and distribution channel.

Breakup by Product:

Radiodermatitis Market by Products

  • Topical
    • Corticosteroids
    • Hydrophilic Creams
    • Antibiotics
    • Others
  • Oral
  • Dressings
    • Hydrogel and Hydrocolloid Dressings
    • No Sting Barrier Film
    • Honey Impregnated Gauze
    • Silicone Coated Dressings
    • Others
       

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
     

Breakup by Region:

Radiodermatitis Market by Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB and Stratpharma AG.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Million USD
Segment Coverage Product, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB and Stratpharma AG
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global radiodermatitis market was valued at USD 514.8 Million in 2024.

We expect the global radiodermatitis market to exhibit a CAGR of 2.94% during 2025-2033.

The sudden outbreak of the COVID-19 pandemic had led to postponement of elective radiodermatitis treatments to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals.

The rising demand for radiodermatitis treatment to reduce discomfort, minimize pain, and prevent interruption in ongoing radiation therapy, which is used to treat cancer, is primarily driving the global radiodermatitis market.

Based on the product, the global radiodermatitis market has been segmented into topical, oral, and dressings. Currently, topical holds the majority of the total market share.

Based on the distribution channel, the global radiodermatitis market can be divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, retail pharmacy exhibits a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where Asia-Pacific currently dominates the global market.

Some of the major players in the global radiodermatitis market include 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Mölnlycke Health Care AB, and Stratpharma AG.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Radiodermatitis Market Report by Product (Topical, Oral, Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials